Rangaprasad (Ranga) Sarangarajan, Ph.D., is the Chief Scientific Officer and SVP Clinical and Translational Sciences at BERG. He has oversight on all R&D activities and involved in the strategic planning and implementation of activities related to pharmaceutical and clinical developmental activities.
Dr. Sarangarajan is the co-inventor and co-architect of the BERG Interrogative Biology® technology; currently focused on next generation R&D innovation in the integration of artificial intelligence based analytics, bioinformatics and RWD/RWE utility for speeding up identification/validation of targets, tractability, drug discovery & pharmaceutical development.
Dr. Sarangarajan has numerous US and international patents (granted and pending), covering areas of the discovery platform, cancer, neurology, metabolic diseases, diabetes, obesity and diagnostics. He has published extensively and has presented his research in national and international medical and scientific meetings. He co-authored and co-edited Cellular Respiration and Carcinogenesis, a first of its kind treatise on the role of mitochondrial function and metabolic network regulation in the etiology of cancer as it pertains to the seminal observations made by Otto Warburg.
Dr. Sarangarajan has a B.S. in Pharmacy and graduate degree in Pharmaceutical Sciences from the University of Cincinnati College of Pharmacy with focus on pharmacology and toxicology. He went on to pursue post-graduate training in genetics, molecular and cell biology for several years prior to joining Massachusetts College of Pharmacy and Health Sciences (now MCPHS University) and served in capacity of Assistant/Associate Professor.
Peter Henstock is the Machine Learning & AI Lead in the Quantitative Data Science group at Pfizer. His work has focused at the intersection of AI, visualization, statistics and software engineering applied mostly to drug discovery but more recently to clinical trials. Peter holds a PhD in Artificial Intelligence from Purdue University along with 6 Master’s degrees. He was recognized as being among the top 12 leaders in AI and Pharma globally by the Deep Knowledge Analytics group. He also currently teaches graduate AI, Software Engineering, and Computer Vision courses at Harvard.
Ankit Lodha has high-end expertise in clinical analytics and interpretation of clinical operations data in the pharmaceutical/ biotechnology industry. In his current position, Ankit is responsible for building the Takeds’s (L-Shire) organization capability as a world-class leader in measuring CROs clinical analytics performance metrics and functional reporting. He is also responsible for designing meaningful metrics, setting the data strategy supporting the measurement of CRO performance, generating real-time dashboard for patient enrollment, site quality and forecasting study start-ups and cycle times. Before this position he has worked at Amgen, AstraZeneca and Pfizer within their respective Analytics and Innovation groups providing strategic services, supporting the metrics and data management needs of senior leadership. He holds a Bachelors in Biotechnology Engineering from Dr. D.Y. Patil University, Masters in Business of Bioscience from Keck Graduate Institute and MBA from University of Redlands – School of Business.
Susan Marlin is the President and CEO of Clinical Trials Ontario (CTO), an organization established by the Province of Ontario to make Ontario a preferred location for clinical trials while maintaining the highest ethical standards. Prior to joining CTO she served as the Associate Vice-Principal at Queen’s University. Susan worked with the National Cancer Institute of Canada Clinical Trials Group for many years, coordinating cancer clinical trials and leading the development of the Ethics and Regulatory Office.
Susan served as President of the Canadian Association of Research Ethics Boards, and as a member of the Canadian Institutes of Health Research (CIHR) Research Integrity Committee, the Ontario Cancer Research Ethics Board, the Tri-Agency Panel on the Responsible Conduct of Research, and the Ontario Government Life Sciences Working Group. She is currently a member of the Life Sciences Ontario Board of Directors and the Management Team for the Ontario SPOR (Strategy for Patient Oriented Research) Support Unit.
Susan was born and raised in Halifax, Nova Scotia. She holds a BSc (Hons) from Dalhousie University, and an MSc in Community Health and Epidemiology from Queen’s University. She was awarded the Queen’s Elizabeth II Diamond Jubilee medal in 2012 in recognition of her work in support of military and veteran health research.
Zoran Antonijevic is Head of Biometrics at MedSource. He held executive positions in Pharmaceutical Companies and CROs and has designed more than 100 clinical trials in numerous therapeutic areas, many of which included adaptive designs. Zoran is a long-time Chair and leader of the DIA Adaptive Design Scientific Working Group. He has authored numerous papers and scientific presentations and was editor of books “Optimization of Pharmaceutical R&D Programs and Portfolios” and “Platform Trials in Drug Development”.
